Phosphoinositide 3-kinase (PI3K) Inhibitors
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.592 alerts
Get alerted when Policy 5.01.592 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and prior authorization for specified oral phosphoinositide 3-kinase (PI3K) pathway inhibitors used to treat selected cancers, activated PI3K delta syndrome, and PIK3CA-related overgrowth spectrum. The requirements apply to providers submitting coverage requests for these medications.
Added Truqap (capivasertib) coverage criteria for adults with metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient.
Removed Aliqopa (copanlisib) coverage criteria because the medication was discontinued.
Updated the initial authorization period for all other reviews of listed oral drugs from 3 months to 6 months.
Updated Piqray (alpelisib) breast cancer criteria to limit the dose to 300 mg once daily.
Removed the ECOG performance status requirement of 0 or 1 from Itovebi (inavolisib) criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.